Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B

SB 9200, an oral prodrug of the dinucleotide SB 9000, is being developed for the treatment of chronic hepatitis B virus (HBV) infection and represents a novel class of antivirals. SB 9200 is thought to activate the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Korolowicz, Kyle E., Iyer, Radhakrishnan P., Czerwinski, Stefanie, Suresh, Manasa, Yang, Junming, Padmanabhan, Seetharamaiyer, Sheri, Anjaneyulu, Pandey, Rajendra K., Skell, Jeffrey, Marquis, Judith K., Kallakury, Bhaskar V., Tucker, Robin D., Menne, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995001/
https://www.ncbi.nlm.nih.gov/pubmed/27552102
http://dx.doi.org/10.1371/journal.pone.0161313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995001/
https://www.ncbi.nlm.nih.gov/pubmed/27552102
http://dx.doi.org/10.1371/journal.pone.0161313

Ejemplares similares